NCT01147107View on ClinicalTrials.gov

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 1, 2016

Study Completion Date

June 1, 2021

Conditions
Hepatitis C, ChronicHIV Infection
Interventions
DRUG

Raltegravir

Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily

DRUG

Efavirenz

Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily

Trial Locations (2)

Unknown

Viet Tiep General Hospital, Haiphong

Hospital for Tropical Diseases, Ho Chi Minh City

All Listed Sponsors
collaborator

Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

OTHER

collaborator

Viet Tiep Hospital

OTHER

collaborator

Oxford University Clinical Research Unit, Vietnam

OTHER

lead

University of Hawaii

OTHER

NCT01147107 - Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection | Biotech Hunter | Biotech Hunter